Zobrazeno 1 - 10
of 27
pro vyhledávání: '"D. Vassilief"'
Autor:
Christian Rose, Aspasia Stamatoullas, Gfm, Pierre Morel, Agnès Guerci, D. Vassilief, François Dreyfus, Marie Pierre Chaury, Pierre Fenaux, Odile Beyne-Rauzy, Dalila Larbaa, Stéphane Cheze, Sabine Brechignac, Lydie Roy, Laurent Pascal
Publikováno v:
Leukemia Research. 34:864-870
Background Iron chelation therapy (CT) improves survival in thalassemia major but its beneficial effects on survival in MDS patients remain uncertain. Methods We analyzed, by multivariate analysis, survival and causes of deaths in 97 low or intermedi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f063b07d529ce067f5686134e81ef27
https://doi.org/10.1016/j.leukres.2009.12.004
https://doi.org/10.1016/j.leukres.2009.12.004
Autor:
Ghandi Damaj, Odile Beyne-Rauzy, Borhane Slama, Stéphane Cheze, E. Berger, Francois Dreyfus, A. Kolb, L. Ades, F Bauduer, S Ayari, Raphael Itzykson, Norbert Vey, Felipe Suarez, Laurence Legros, Xavier Thomas, Martine Gardembas, Fatiha Chermat, M.C. Chaury, D. Vassilief, Pierre Fenaux, Agnès Guerci, Aspasia Stamatoullas
Publikováno v:
Leukemia. 23:673-678
Erythropoiesis-stimulating agents (ESAs) remain the first-line treatment of anemia in lower risk myelodysplastic syndromes (MDS) without 5q deletion. A preliminary report suggested that adding all-trans retinoic acid (ATRA) to ESAs may improve their
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccf8707aea70d5bd3e33dcdf9606288c
https://doi.org/10.1038/leu.2008.362
https://doi.org/10.1038/leu.2008.362
Autor:
Bruno Varet, Marie Christine Rousselet, Fanny Gaillard, Marie Catherine Quarre, Beatrice Mahe, Odile Beyne-Rauzy, Martine Gardembas, Achille Aouba, Anne Moreau, Stéphanie Dubois, D. Vassilief, Micheline Tulliez, Pierre Fenaux, Laurence Legros, Philippe Rousselot, Didier Bouscary, Stéphane Giraudier, Agnès Guerci, François Dreyfus, Norbert Ifrah
Publikováno v:
British Journal of Haematology. 131:609-618
Summary Patients (n = 47) with low-risk myelodysplastic syndrome were treated with thalidomide [200 mg/d, increased by 200 mg/d/4 weeks up to week 16]. Responses were evaluated according to the International Working Group criteria at week 16 for 39 p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6a96f247bb6cfe02324c48809b9b453
https://doi.org/10.1111/j.1365-2141.2005.05817.x
https://doi.org/10.1111/j.1365-2141.2005.05817.x
Autor:
N. Ounnoughène, P. Molho, I. Lopez, Claude Negrier, J. Goudemand, U. Assogba, M. A.‐Dumont, M.‐C. Quarrè, D. Vassilief, F. Driss, Patricia Paugy, D. Magli‐Barioz
Publikováno v:
Haemophilia. 10:572-581
Summary. The aims of the study were to evaluate the impact of a written information about treatment related risks in patient receiving blood derived or recombinant medications. Haemophiliac patients and patients with constitutional or acquired immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3e45ba01cfd564b3323db64cea2ba1a
https://doi.org/10.1111/j.1365-2516.2004.00930.x
https://doi.org/10.1111/j.1365-2516.2004.00930.x
Autor:
Michaella Fontenay-Roupie, Marie Catherine Quarre, François Dreyfus, D. Vassilief, Nicole Casadevall, Simona Zompi, Franck Viguié, Katayoun Jondeau, Didier Bouscary
Publikováno v:
Leukemia & Lymphoma. 33:607-611
We report here a very unusual patient with Polycythemia vera treated with Pipobroman who developed severe aplastic anemia following administration of the drug. Six months later, because of lack of response, cyclosporine therapy was given there was ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffb33afd9855f6e6113a04672d06010d
https://doi.org/10.3109/10428199909058468
https://doi.org/10.3109/10428199909058468
Autor:
Christian Berthou, B. Quesnel, Didier Bouscary, Laurence Sanhes, Odile Beyne-Rauzy, Chadi Al-Nawakil, Pierre Fenaux, Aspasia Stamatoullas, Norbert Vey, Francois Dreyfus, Anne Vekhoff, Jerome Tamburini, Martine Gardembas, Beatrice Mahe, Borhane Slama, Jean-Jacques Sotto, D. Vassilief, Sophie Park, Achille Aouba, Caroline Elie
Publikováno v:
Leukemia research. 33(4)
Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes J. Tamburini a,∗, C. Elie b, S. Park a, O. Beyne-Rauzy c, M. Gardembas d, C. Berthou e, B. Mahe f, L. Sanhes g, A. Stamatoullas h, N. Vey i, A. Ao
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24482e03f15dddfd7fa80b8896a6639b
https://pubmed.ncbi.nlm.nih.gov/18640718
https://pubmed.ncbi.nlm.nih.gov/18640718
Autor:
Dalila Larbaa, D. Vassilief, Stéphane Cheze, Pierre Fenaux, Dominique Bordessoule, Agnès Guerci, Odile Beyne-Rauzy, Lydia Roy, Christian Rose, François Dreyfus, Aspasia Stamatoullas, Sabine Brechignac, Bruno Quesnel, Lydia Dumazert, Beatrice Mahe
Publikováno v:
Blood. 110:249-249
Background: RBC transfusions are required in most MDS, leading to iron overload which probably contributes to shortened survival (Malcovati, JCO, 2005). Consensus for indications of iron chelation therapy (CT) in MDS patients are recent (Gattermann H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0a7568db292b798fdad3c4693d2721d
https://doi.org/10.1182/blood.v110.11.249.249
https://doi.org/10.1182/blood.v110.11.249.249
Autor:
Norbert Vey, Laurence Legros, Lionel Adès, Aspasia Stamatoullas, Augustin Ferrant, Hervé Dombret, Sophie Park, L. Aljassem, Charikleia Kelaidi, Stéphane Giraudier, Stéphane Cheze, Francois Dreyfus, V. Andrieux, Lionel Mannone, Sophie Grabar, Valérie Bardet, D. Vassilief, M.C. Quarre, Beatrice Mahe, Nicole Casadevall, Pierre Fenaux, Martine Escoffre-Barbe, Odile Beyne-Rauzy, S. de Botton, Christophe Ravoet
Publikováno v:
Blood. 108:522-522
Background: EPO and its derivative darbepoietin alfa (DAR) are important treatments of anemia in lower risk MDS. Prognostic factors of response and of its duration have been recently updated (Blood, 2005, 106, 803–11) and we reanalyzed them in a la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5061e3f003e301bc8053c0b93b1a0d93
https://doi.org/10.1182/blood.v108.11.522.522
https://doi.org/10.1182/blood.v108.11.522.522
Autor:
Caroline Elie, Francois Dreyfus, Achille Aouba, Pierre Fenaux, Agnès Guerci, Frédéric Bauduer, Martine Gardembas, Jerome Tamburini, D. Vassilief, Christian Berthou, Didier Bouscary, M.C. Quarre, S. Vaultier, Laurence Legros, Aspasia Stamatoullas, Laurence Sanhes, Jean-Jacques Sotto, Odile Beyne-Rauzy
Publikováno v:
Blood. 108:2673-2673
Background: Thal has shown some efficacy in low risk MDS, but with dose-limiting toxicity requiring discontinuation in > 50% pts (Bouscary D, BJH, 2005, 131, 609 and other groups). Thus we assessed Thal at lower dose in such MDS. Methods: From Jan 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d56397a1549b0c95dc16fea61763f98
https://doi.org/10.1182/blood.v108.11.2673.2673
https://doi.org/10.1182/blood.v108.11.2673.2673
Autor:
Francois Dreyfus, Agnès Guerci, Christian Rose, Odile Beyne-Rauzy, Sabine Brechignac, F. Courtois, Lydia Roy, D. Vassilief, Béatrice Mahé, Pierre Fenaux, M.P. Chaury, B. Lefs, Bruno Quesnel, Mathieu Wemeau, Aspasia Stamatoulas
Publikováno v:
Blood. 108:2661-2661
Background: RBC transfusions remain a mainstay in the treatment in MDS, but their characteristics in a large MDS population have not been reported in detail. Indications of iron chelation therapy (CT) in those patients, are based on consensus (Gatter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::465ddd5c21f22361dd45f64ac145f947
https://doi.org/10.1182/blood.v108.11.2661.2661
https://doi.org/10.1182/blood.v108.11.2661.2661